Cite
Elliot ER, Amara A, Pagani N, et al. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. J Antimicrob Chemother. 2017;72(7):2143doi: 10.1093/jac/dkx145.
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., Higgs, C., Khoo, S., & Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. The Journal of antimicrobial chemotherapy, 72(7), 2143. https://doi.org/10.1093/jac/dkx145
Elliot, Emilie R, et al. "Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge." The Journal of antimicrobial chemotherapy vol. 72,7 (2017): 2143. doi: https://doi.org/10.1093/jac/dkx145
Elliot ER, Amara A, Pagani N, Else L, Moyle G, Schoolmeesters A, Higgs C, Khoo S, Boffito M. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. J Antimicrob Chemother. 2017 Jul 01;72(7):2143. doi: 10.1093/jac/dkx145. PMID: 28482097.
Copy
Download .nbib